Company: CRNX
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0000950170-25-057452
Chunk: 29

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 29
---
 as Exhibit 19 to our Annual Report on Form 10-K for the year ended December 31, 2024.

Prohibition Against Pledging and Hedging

Our Insider Trading Compliance Policy also prohibits our officers, directors and employees pledging our stock as collateral to secure loans and from engaging in hedging transactions, including zero-cost collars and forward sale contracts. It further prohibits margin purchases of our stock, short sales of our stock, and any transactions in puts, calls or other derivative securities involving our stock.

Corporate Governance

Our company’s Code of Business Conduct and Ethics, Corporate Governance Guidelines, Audit Committee Charter, Compensation Committee Charter, Nominating and Corporate Governance Committee Charter, Research and Development Committee Charter and Global Therapeutics Strategy and Access Committee Charter are available, free of charge, on our website at www.crinetics.com. Please note, however, that the information contained on the website is not incorporated by reference in, or considered part of, this proxy statement. We will also provide copies of these documents and our company’s other corporate governance documents, free of charge, to any stockholder upon written request to Crinetics Pharmaceuticals, Inc., 6055 Lusk Boulevard, San Diego, CA 92121, Attention: Corporate Secretary.

Director Compensation

In March 2024, after consultation with Aon’s Human Capital Solutions practice, a division of Aon plc, or Aon, regarding director compensation relative to the market and our peer group, our board of directors, upon recommendation from the compensation committee, adopted an amended non-employee director compensation program, effective as of June 7, 2024, as follows: (1) our non-employee directors receive an annual retainer of $41,000, with an additional $30,000 annual retainer payable to the Chair of the board of directors; (2) non-employee directors serving as the chairs of the audit, compensation, nominating and corporate governance and research and development committees receive additional annual retainers of $20,000, $15,000, $10,000 and $15,000, respectively; (3) non-employee directors serving as members (but not chairs) of the audit, compensation, nominating and corporate governance and research and development committees receive additional annual retainers of $10,000, $7,500, $5,000 and $7,500, respectively; (4) each non-employee director who is initially elected or appointed to the board of directors receives an initial grant of options to